Four Sets of Complementary Binding Sites Involved in Fibrin Polymerization.

1979 ◽  
Author(s):  
Stephanie A. Olexa ◽  
Andrei Z. Budzynski

Activation of fibrinogen by thrombin releases fibrinopeptides A and B, followed by the formation of an ordered fibrin polymer, probably due to the association of complementary binding sites. The present investigation focused on defining areas of fibrin monomer molecule which are active during polymerization by identifying binding regions on plasmic degradation products of fibrinogen or fibrin. Studies were done in soluble and in solid phase systems. In the first, species were mixed in solution and monitored for complex formation on Tris-glycine gels; in the latter, affinity chromatography on insolublized fibrinogen, fibrin monomer or cross linked fibrin was done. Thrombin-treated fibrinogen, Fragments X, Y, or NDSK bound to Fragment DD in solution as well as to all three insolublized species. Therefore one type of polymerization site is present and available on the Fragment D region of fibrinogen. The complementary site is a thrombin activated region on th e NH2-terminal domain of fibrinogen. Fragments E1 and E2 from crosslinked fibrin complexed with Fragment DD but not with fibrinogen, Fragments X, Y, or D. Fragment E1 and E2 also bound to insolublized crosslinked fibrin but not to insolublized fibrinogen or fiorin monomer. The data indicate that Fragment DD contains a binding site generated in the aligned Fragment D moieties which is inoperative in a single Fragment D. This site is complementary to the fourth site, a thrombin-activated region on the NH2-terminal domain of fibrinogen localized to Fragments E1 and E2. It is concluded that the first two binding sites are active on fibrin monomer molecules but the other two sites become operative only after the formation of fibrin oligomers.

1981 ◽  
Author(s):  
Stephanie A Olexa

Fibrinogen is converted to fibrin monomer by thrombin, which cleaves the fibrinopeptides A and E. The resulting fibrin monomers spontaneously polymerize to form a fibrin network, which is later stabilized with covalent crosslinking bonds. Although the action of thrombin and Factor XHIa have been fairly well defined, the mechanism of fibrin polymerization is not yet understood. Electron microscopy and light scattering studies have provided information on the arrangement of molecules within the fiber. Monomers appear to align with a half-staggered overlap, resulting in a fiber with a width equal to twice that of fibrinogen. Detailed studies on the location and interaction of polymerization sites have been done primarily by using fibrinogen and fibrin degradation products. The studies indicate that polymerization is due to the interaction of complementary binding sites which are located on the Fragment D and the NH2- terminal domains in the fibrinogen molecule. One of these sites, located in the sequence 373410 of the gamma chain, is available on fibrinogen in the Fragment D domain. This site is complementary to the site revealed by the loss of fibrinopeptide A, which is probably located in the sequence contiguous to PPA. A second polymerization site in the NH2- terminal domain of fibrin may be located in the sequence following fibrinopeptide B. The recriprocal site may also be located on the Fragment D region. The polymerization of fibrin appears to be due to a complex interaction between molecules with both the primary sequence and the three-dimensional conformation having vital roles.


1981 ◽  
Author(s):  
Stephanie A Olexa ◽  
Andrei Z Budzynski

The formation of a fibrin clot is initiated after the proteolytic cleavage of fibrinogen by thrombin. The enzyme removes fibrinopeptides A and B, and generates fibrin monomer which spontaneously polymerizes. Polymerization appears to occur through the interaction of complementary binding sites on the NH2- and COOH- terminal regions of the molecules since Fragment D1, encompassing the COOH-terminals of the β and γ chains, binds to thrombin-treated NDSK which contains N2-terminals of the α , β and γ chains. A peptide of 4,200 molecular weight has been isolated from the y chain remnant of fibrinogen Fragment D1 which has the ability to bind to the NH2- terminal region of fibrin monomer, thus inhibiting fibrin monomer polymerization. The peptide reduces the maximum rate and extent of the polymerization of thrombin or batroxobin fibrin monomer and increases the lag time of the reaction. The D1 peptide does not interact with NDSK, fibrinogen or Fragment D1but it binds to thrombin-treated NDSK with a Kd of 1.45 x 106 m and approximately two binding sites per molecule of NDSK have been found. Fibrin monomer formed either by thrombin or batroxobin binds approximately two molecules of D1 peptide per molecule of fibrin monomer, indicating that the complementary site is revealed by the loss of fibrinopeptide A. The NH2- terminal amino acid sequence (Thr-Arg-Trp) and the COOHterminal sequence (Ala-Gly-Asp-Val) of the D1 peptide were determined. Therefore the γ 373-410 region of the fibrinogen molecule contains a polymerization site which is complementary to the thrombin-activated site on the NH2terminal region of fibrinogen. The binding site on the Dl peptide has the characteristics of the polymerization site which is exposed and available on the COOH-terminal region of the fibrinogen molecule without any participation of thrombin.


2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Alaa F. Nahhas ◽  
Thomas J. Webster

AbstractMolecular imprinting (MI) is a technique that creates a template of a molecule for improving complementary binding sites in terms of size and shape to a peptide, protein, bacteria, mammalian cell, or virus on soft materials (such as polymers, hydrogels, or self-assembled materials). MI has been widely investigated for over 90 years in various industries but is now focused on improved tissue engineering, regenerative medicine, drug delivery, sensors, diagnostics, therapeutics and other medical applications. Molecular targets that have been studied so far in MI include those for the major antigenic determinants of microorganisms (like bacteria or viruses) leading to innovations in disease diagnosis via solid-phase extraction separation and biomimetic sensors. As such, although not widely investigated yet, MI demonstrates much promise for improving the detection of and treatment for the current Coronavirus Disease of 2019 (COVID-2019) pandemic as well as future pandemics. In this manner, this review will introduce the numerous applications of MI polymers, particularly using proteins and peptides, and how these MI polymers can be used as improved diagnostic and therapeutic tools for COVID-19. Graphic Abstract


2021 ◽  
Author(s):  
Bobbi Stromer ◽  
Rebecca Crouch ◽  
Katrinka Wayne ◽  
Ashley Kimble ◽  
Jared Smith ◽  
...  

Standard methods are in place for analysis of 17 legacy munitions compounds and one surrogate in water and soil matrices; however, several insensitive munition (IM) and degradation products are not part of these analytical procedures. This lack could lead to inaccurate determinations of munitions in environmental samples by either not measuring for IM compounds or using methods not designed for IM and other legacy compounds. This work seeks to continue expanding the list of target analytes currently included in the US Environmental Protection Agency (EPA) Method 8330B. This technical report presents three methods capable of detecting 29 legacy, IM, and degradation products in a single High Performance Liquid Chromatography (HPLC) method with either ultraviolet (UV)-visible absorbance detection or mass spectrometric detection. Procedures were developed from previously published works and include the addition of hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine (MNX); hexahydro-1,3-dinitroso-5-nitro-1,3,5-triazine (DNX); hexahydro-1,3,5-trinitroso-1,3,5-triazine (TNX); 2,4-diamino-6-nitrotoluene (2,4-DANT); and 2,6-diamino-4-nitrotoluene (2,6-DANT). One primary analytical method and two secondary (confirmation) methods were developed capable of detecting 29 analytes and two surrogates. Methods for high water concentrations (direct injection), low-level water concentrations (solid phase extraction), soil (solvent extraction), and tissue (solvent extraction) were tested for analyte recovery of the new compounds.


2021 ◽  
Author(s):  
◽  
Liliia Mavliutova

Sialic acids are an important family of monosaccharides that are typically found as terminal moieties of glycans. Aberrant sialylation has been proven to correlate with various diseases including cancer. Glycosylation analysis is complex due to high diversityof the glycan isomers and their low abundance. Antibodies and lectins are commonly used in glycan purification and enrichment. However, high cost, poor availability, and limitation in storage/testing conditions hinders their application on a broader scale. This thesis is focused on the development of alternative glycan specific receptors with their potential applications in glycomics and cell imaging. The underlying technique for producing the synthetic receptors is molecular imprinting. Highly complementary binding sites are formed by fixing pre-ordered template/functional monomer complexes into a highly crosslinked polymer matrix. Fundamental investigation of this intermolecular imprinting approach in the imprinting of glycosylated targets is reported here. The core of this study focuses on the elucidation of relative contribution of orthogonally interacting functional monomers, their structural tuning and the importance of monomer, solvent and counterion choice on the imprinting. Molecularly imprinted polymers (MIPs) are developed as particles of different sizes for glycan/glycopeptide enrichment applications or combined with fluorescent reportergroups for use as glycan imaging nanolabels. Special attention is given to the improvement of sialic acid MIP selectivities toward particular structures associated with cancer biomarkers. Development of MIPs against such complex targets includes design of linkage selective MIPs with comprehensive studies of the affinities and selectivities of the final glycan specific materials.


PLoS ONE ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. e51660 ◽  
Author(s):  
Yi-Liang Liu ◽  
I-Chen Tsai ◽  
Chia-Wei Chang ◽  
Ya-Fan Liao ◽  
Guang-Yaw Liu ◽  
...  

1998 ◽  
Vol 140 (5) ◽  
pp. 1055-1062 ◽  
Author(s):  
Alexandre Benmerah ◽  
Christophe Lamaze ◽  
Bernadette Bègue ◽  
Sandra L. Schmid ◽  
Alice Dautry-Varsat ◽  
...  

We have previously shown that the protein Eps15 is constitutively associated with the plasma membrane adaptor complex, AP-2, suggesting its possible role in endocytosis. To explore the role of Eps15 and the function of AP-2/Eps15 association in endocytosis, the Eps15 binding domain for AP-2 was precisely delineated. The entire COOH-terminal domain of Eps15 or a mutant form lacking all the AP-2–binding sites was fused to the green fluorescent protein (GFP), and these constructs were transiently transfected in HeLa cells. Overexpression of the fusion protein containing the entire COOH-terminal domain of Eps15 strongly inhibited endocytosis of transferrin, whereas the fusion protein in which the AP-2–binding sites had been deleted had no effect. These results were confirmed in a cell-free assay that uses perforated A431 cells to follow the first steps of coated vesicle formation at the plasma membrane. Addition of Eps15-derived glutathione-S-transferase fusion proteins containing the AP-2–binding site in this assay inhibited not only constitutive endocytosis of transferrin but also ligand-induced endocytosis of epidermal growth factor. This inhibition could be ascribed to a competition between the fusion protein and endogenous Eps15 for AP-2 binding. Altogether, these results show that interaction of Eps15 with AP-2 is required for efficient receptor-mediated endocytosis and thus provide the first evidence that Eps15 is involved in the function of plasma membrane–coated pits.


Sign in / Sign up

Export Citation Format

Share Document